U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Ovarian Clear Cell Adenocarcinoma

MedGen UID:
1734896
•Concept ID:
C5418893
•
Neoplastic Process

Definition

Ovarian clear cell adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Ovarian Clear Cell Adenocarcinoma

Professional guidelines

PubMed

Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD
Gynecol Oncol 2021 Sep;162(3):741-750. Epub 2021 Jul 8 doi: 10.1016/j.ygyno.2021.06.033. PMID: 34247767
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. PMID: 33545690
Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
Takahashi K, Takenaka M, Kawabata A, Yanaihara N, Okamoto A
Int J Clin Oncol 2020 Mar;25(3):425-431. Epub 2020 Jan 27 doi: 10.1007/s10147-020-01625-w. PMID: 31989349

Recent clinical studies

Therapy

Top advances of the year: Ovarian cancer.
Lumish MA, Kohn EC, Tew WP
Cancer 2024 Mar 15;130(6):837-845. Epub 2023 Dec 15 doi: 10.1002/cncr.35135. PMID: 38100616
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Fujiwara S
Jpn J Clin Oncol 2023 Jul 31;53(8):664-672. doi: 10.1093/jjco/hyad057. PMID: 37288485
New therapies for clear cell ovarian carcinoma.
Stewart J, Cunningham N, Banerjee S
Int J Gynecol Cancer 2023 Mar 6;33(3):385-393. doi: 10.1136/ijgc-2022-003704. PMID: 36878571
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD
Gynecol Oncol 2021 Sep;162(3):741-750. Epub 2021 Jul 8 doi: 10.1016/j.ygyno.2021.06.033. PMID: 34247767
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA
Ann Oncol 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135. PMID: 31046082

Prognosis

Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer.
Mori Y, Okimoto Y, Sakai H, Kanda Y, Ohata H, Shiokawa D, Suzuki M, Yoshida H, Ueda H, Sekizuka T, Tamura R, Yamawaki K, Ishiguro T, Mateos RN, Shiraishi Y, Yatabe Y, Hamada A, Yoshihara K, Enomoto T, Okamoto K
Cell Rep Med 2024 May 21;5(5):101532. Epub 2024 Apr 25 doi: 10.1016/j.xcrm.2024.101532. PMID: 38670097Free PMC Article
New therapies for clear cell ovarian carcinoma.
Stewart J, Cunningham N, Banerjee S
Int J Gynecol Cancer 2023 Mar 6;33(3):385-393. doi: 10.1136/ijgc-2022-003704. PMID: 36878571
MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis.
Wang CK, Chen TJ, Tan GYT, Chang FP, Sridharan S, Yu CA, Chang YH, Chen YJ, Cheng LT, Hwang-Verslues WW
Cancer Res 2023 Jan 18;83(2):251-263. doi: 10.1158/0008-5472.CAN-22-1159. PMID: 36354374Free PMC Article
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD
Gynecol Oncol 2021 Sep;162(3):741-750. Epub 2021 Jul 8 doi: 10.1016/j.ygyno.2021.06.033. PMID: 34247767
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA
Ann Oncol 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135. PMID: 31046082

Clinical prediction guides

Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH, Oliveira DNP, Christiansen AP, Høgdall C, Høgdall E
Cancer Genet 2023 Nov;278-279:9-16. Epub 2023 Aug 3 doi: 10.1016/j.cancergen.2023.08.001. PMID: 37567101
Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A
Am J Surg Pathol 2023 Jun 1;47(6):635-648. Epub 2023 Apr 6 doi: 10.1097/PAS.0000000000002039. PMID: 37026792
New therapies for clear cell ovarian carcinoma.
Stewart J, Cunningham N, Banerjee S
Int J Gynecol Cancer 2023 Mar 6;33(3):385-393. doi: 10.1136/ijgc-2022-003704. PMID: 36878571
MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis.
Wang CK, Chen TJ, Tan GYT, Chang FP, Sridharan S, Yu CA, Chang YH, Chen YJ, Cheng LT, Hwang-Verslues WW
Cancer Res 2023 Jan 18;83(2):251-263. doi: 10.1158/0008-5472.CAN-22-1159. PMID: 36354374Free PMC Article
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA
Ann Oncol 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135. PMID: 31046082

Recent systematic reviews

Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, Shimada M, Machida H, Mikami M, Klar M, Roman LD, Wright JD, Sood AK, Gershenson DM
JAMA Netw Open 2023 Jun 1;6(6):e2318602. doi: 10.1001/jamanetworkopen.2023.18602. PMID: 37326992Free PMC Article
Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis.
Didar H, Farzaneh F, Najafiarab H, Namakin K, Gohari K, Sheidaei A, Ramezani S
Curr Med Res Opin 2023 Jun;39(6):901-910. Epub 2023 May 7 doi: 10.1080/03007995.2023.2208488. PMID: 37104696

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...